ARS Pharmaceuticals, Inc. (SPRY) Misses Q1 EPS by 12c, Beats on Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update
May 15, 2026 6:00 AM EDTQ1 2026 total revenue of $22.7 million including neffy® (epinephrine nasal spray) U.S. net product
revenue of $17.5 million
CVS Caremark proposal in final stages of approval process; definitive update anticipated in early June
Sales force expansion to 148 representatives completed
Phase 2b CSU study interim population fully enrolled, and on track for Q4 2026 readout
Conference call to be held today, May 15, 2026, at 5:30 a.m. PT / 8:30 a.m. ET
SAN DIEGO, May 15, 2026 (GLOBE... More
